EC approves Kineret for CAPS

The European Commission approved an application to expand the label of Kineret anakinra from Swedish Orphan Biovitrum AB (SSE:SOBI) to include treatment of cryopyrin-associated periodic syndromes (CAPS). The IL-1 receptor antagonist is already approved in the U.S. and EU to treat rheumatoid arthritis and in the U.S. to treat neonatal onset multisystem inflammatory disease (NOMID), the most severe form of CAPS. Swedish Orphan has exclusive, worldwide rights to Kineret from Amgen Inc. (NASDAQ:AMGN) (see BioCentury Extra, Nov. 19, 2012). ...